Press Releases

Press Releases

Research presented at the Annual Meeting of the Society of Biological Psychiatry and of the American Society of Clinical Psychopharmacology   highlight fundamentally differentiated mechanism of action for PH94B These preclinical data demonstrate that intranasal radiolabelled-PH94B is largely
Companies plan to initiate the global study of PH94B for the acute treatment of social anxiety disorder (SAD) in the second half of 2022 Trial designed to support commercialization of PH94B in China and other markets outside the U.S. SOUTH SAN FRANCISCO, Calif. & SHANGHAI --(BUSINESS WIRE)--Apr.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, neuro-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other central
Advancing late-stage PH94B clinical program, including: Progress towards topline data readouts for PALISADE-1 and PALISADE-2 Phase 3 trials designed to evaluate PH94B in social anxiety disorder (SAD) that are expected in mid-2022 and second half 2022, respectively; PALISADE Long-term Safety Study
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other
SOUTH SAN FRANCISCO, Calif. , Nov. 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression,
PALISADE Phase 3 clinical trials of PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan PH94B Phase 2A clinical program targeting additional potential anxiety indications launched in adjustment disorder with anxiety (AjDA) Newly
SOUTH SAN FRANCISCO, Calif. , Nov. 04, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central
Study Launches Phase 2A Clinical Program Designed to Explore PH94B’s Potential in Multiple Additional Anxiety Disorders Phase 2A Study in Adjustment Disorder to Run in Parallel with Ongoing Phase 3 Studies in Acute Treatment of Social Anxiety Disorder SOUTH SAN FRANCISCO, Calif. , Oct.
Preclinical study of intranasal radiolabeled PH94B in laboratory rats further differentiates PH94B’s mechanism of action from benzodiazepines SOUTH SAN FRANCISCO, Calif. , Oct. 05, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing a new generation
Displaying 11 - 20 of 197